Non-alcoholic steatohepatitis (NASH) is increasing in prevalence, partially because of the pervasiveness of obesity. In this Review, Musso and colleagues discuss potential future approaches to treat this disease, including those that target causes, such as inflammation and aberrant metabolism, as well as those that target fibrosis, one of the key features of patients with NASH.
- Giovanni Musso
- Maurizio Cassader
- Roberto Gambino
